Earnings Call Summary | DarioHealth(DRIO.US) Q3 2024 Earnings Conference
Earnings Call Summary | DarioHealth(DRIO.US) Q3 2024 Earnings Conference
Non-GAAP operating expenses were reduced to $12.3 million, a 15.9% sequential decline from Q2 2024.The following is a summary of the DarioHealth Corp. (DRIO) Q3 2024 Earnings Call Transcript:
以下是DarioHealth公司（DRIO）2024年第三季度業績發佈會的總結：
Financial Performance:
財務表現：
DarioHealth reported Q3 revenue of $7.42 million, an increase of 18.7% over Q2 2024 and 111% year-over-year.
Gross margins for the B2B2C business rose to 83%, with overall business gross margins reaching 70% on a non-GAAP basis.
Non-GAAP operating expenses were reduced to $12.3 million, a 15.9% sequential decline from Q2 2024.
DarioHealth報告2024年第三季度營業收入爲742萬美元，較2024年第二季度增長18.7%，同比增長111%。
B2B2C業務的毛利率上升至83%，整體業務的毛利率在非GAAP基礎上達到70%。
非GAAP營業費用減少至1230萬美元，比2024年第二季度下降15.9%。
Business Progress:
業務進展：
DarioHealth has recently integrated Twill, enhancing its platform with advanced behavioral health capabilities.
Achieved 10 new client wins this quarter and is in the process of securing approximately 5 more by the year's end.
Expanding commercial opportunities with GLP-1 product and new prescribing partner.
Introduced a large-scale cardiometabolic program in the Medicaid space and a digital mental health benefit in the Medicare Advantage market with Centene.
DarioHealth最近整合了Twill，增強了其平台的先進行爲健康功能。
本季度實現了10個新客戶的贏得，並正在努力在年底前確保大約5個新客戶。
通過GLP-1產品和新的處方合作伙伴擴展商業機會。
在醫療補助領域推出了大規模心臟代謝項目，並在醫保優選市場與康西哥合作推出數字心理健康福利。
Opportunities:
機會：
DarioHealth's expanded offerings in various health sectors such as behavioral, musculoskeletal, and metabolic health boost its market positioning.
New client acquisitions and expansion into health plan channels with major firms like Centene and Aetna signify growing market influence.
Partnership with AARP potentially opens access to 38 million members aged 50 and older, starting January 2025.
DarioHealth在行爲、肌肉骨骼和代謝健康等多個健康領域的擴展性產品提升了其市場定位。
與康西哥和Aetna等主要公司在健康計劃渠道的客戶獲取和擴展表明其市場影響力在不斷增長。
與AARP的合作有可能使2025年1月起接觸到3800萬名50歲及以上的會員。
Risks:
風險：
Ongoing need to convert new client agreements into meaningful and stable revenues could pose a challenge if not managed efficiently.
The transition from milestone-based to recurring revenue models in the pharma channel requires careful negotiation and client adaptation which might affect predictability in revenue.
將新客戶協議轉化爲有意義和穩定的營業收入的持續需求可能會帶來挑戰，如果管理不當。
製藥渠道從里程碑式收入模式轉向經常性收入模式，需要進行仔細的談判和客戶適應，這可能會影響營業收入的可預測性。
More details: DarioHealth IR
更多詳情：DarioHealth IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由人工智能生成。內容的準確性無法得到完全保證。有關更全面的細節，請參考投資者關係網站。本文僅供投資者參考，不構成任何指導或建議。
